Will Lilly's FDA-Approved Foundayo Pill Erode Novo's Injectable Grip on Obesity?
Eli Lilly secured long-awaited FDA approval for its oral obesity pill orforglipron, branded as Foundayo, marking a pivotal milestone in the GLP-1 weight loss arena. Announced recently, the nod positions Foundayo as the first no-restrictions oral GLP-1 agonist, directly challenging Novo Nordisk's injectable leader Wegovy. Shares of LLY surged 5.6% on the approval day (April 1, 2026), closing at $971.67, while NVO dipped slightly by -0.15%, reflecting investor bets on Lilly's potential to accelerate uptake in a market projected to exceed $100 billion by 2030.
Foundayo's Edge: Oral Convenience Meets Proven Efficacy
Orforglipron's Phase 3 ATTAIN-1 trial delivered compelling results: up to 15% weight loss with a tolerability profile akin to injectable GLP-1s, including GI side effects that taper over time. Unlike injectables requiring weekly shots, Foundayo's daily pill format targets the 25% of U.S. obesity patients citing needle phobia—a segment Lilly executives highlighted in recent earnings calls as ripe for disruption.
Lilly's manufacturing readiness is aggressive: pre-launch inventories hit $952 million by Q3 2025, up from $548 million year-end 2024, signaling confidence in rapid commercialization. Guidance points to a U.S. launch in 2026, with ex-U.S. rollouts in late 2026 (e.g., UAE) and broader 2027 adoption. CEO David Ricks emphasized scaling via LillyDirect, their direct-to-consumer platform that already serves 1 million patients.
| Metric | Lilly (LLY) FY2025 | Novo (NVO) FY2025 |
|---|---|---|
| Revenue | $65.2B (+45% YoY) | DKK 297B (~$43B, +10% YoY) |
| Net Income | $20.6B | DKK 98.5B (~$14.3B) |
| EPS Diluted | $22.95 (+96% YoY) | $23.03 (+2% YoY) |
| Free Cash Flow | $8.97B | DKK 29B (~$4.2B) |
| Market Cap | $918B | $163B |
Lilly's obesity duo—Mounjaro and Zepbound—drove 56% of 2025 revenues, with Q4 revenue hitting $19.3B (+42% YoY). Gross margins expanded to 85%, underscoring pricing power despite Medicare deals capping patient costs at $50/month from July 2026.
Novo's Response: Guidance Cuts Signal Vulnerability
Novo Nordisk, long the obesity kingpin with Wegovy sales topping DKK 82B in 2025, faces mounting pressure. U.S. obesity market share slipped as Wegovy's prescription leadership yielded to competitors early 2025, per their 20-F filing. Q4 2025 sales declined 8%, prompting 2026 guidance slashed to -5% to -13% sales decline at constant exchange rates—blaming U.S. price erosion, MFN clauses, and GLP-1 dynamics.
NVO's oral semaglutide (Wegovy pill) is filed for EU approval and eyes U.S. 2026 launch, but tolerability lags orforglipron's profile. Compounding threats persist despite FDA shortage resolutions, eroding branded uptake. Earnings Q&A revealed concerns: Wegovy high-dose approval pending, but CapEx peaks at DKK 55B in 2026 to chase capacity.
Price action underscores the tilt: LLY's 1-month return -4.6% masks the approval spike, while NVO plunged -21.9% over the same period and -26.4% YTD. NVO trades at a dirt-cheap P/E TTM 10.2 vs. LLY's 42.2 (fwd 26.8), but growth divergence—LLY 45% revenue CAGR vs. NVO's 6%—justifies the premium.
Uptake Math: Why Foundayo Could Claim 20-30% Oral Share
Patient activation is key. Lilly's international Mounjaro ramp hit stride in Q3 2025 (China, Brazil launches), blending 75% cash-pay with Type 2 diabetes reimbursement in 8 markets. Foundayo expands this: orforglipron's T2D Phase 3 data matched expectations, teeing up dual obesity/diabetes labeling.
Projections: Analysts eye $5-10B peak U.S. sales by 2030 if uptake mirrors Zepbound's trajectory. Needle-fear cohort alone represents 10M+ eligible patients. Competitive response? Novo counters with CagriSema (Phase 3 REDEFINE 11) promising 20%+ weight loss, but injectable format limits reach.
| Valuation Snapshot | LLY | NVO |
|---|---|---|
| P/E Fwd | 26.8 | 11.3 |
| EV/Sales TTM | 14.6 | 3.7 |
| Revenue Growth TTM | 45% | 6% |
| EPS Growth TTM | 95% | 2% |
| 1M Price Return | -4.6% | -21.9% |
Investment Takeaway: Overweight LLY, Trim NVO
Bullish on LLY: Foundayo catapults Lilly toward 60%+ obesity market share, leveraging oral adherence (historically 50% patient preference in T2D) and global scale. At $918B market cap, the stock merits its premium—target $1,100 on 2026 revenue midpoint $81.5B (+25%).
Novo's moat cracks: Neutral to bearish near-term as oral competition bites. Hold for dividend yield 3.6%, but cap exposure amid -26% YTD drawdown.
Watch these catalysts:
- Q1 2026 launch uptake—TRx >1M signals blockbuster.
- NVO's oral semaglutide approval/timeline vs. Foundayo ramp.
- Medicare Part D opt-ins post-July 2026, testing pricing resilience.